212. Long-Term 52-Week Results of Palace 3, A Phase 3, Randomized, Controlled Trial of Apremilast, An Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis and Current Skin Involvement
Details
The content you want is available to Zendy users.Already have an account? Click here. to sign in.